Glaxosmithkline PLC, a large shareholder at Theravance Inc (NASDAQ:THRX) disclosed today the acquisition of 832,456 shares in the open market at a unit price of $12,786,524.16 on November 4, 2014. This is the third purchase by Glaxosmithkline PLC this year, and now indirectly owns 31,581,179 shares.
No other insider has acquired the stock since Senior Vice President Chief Communications, Leonard M. Blum, acquired 677 shares at a unit price of $10.33 back in February, 2010. Since then, Glaxosmithkline PLC has reported seventeen purchases.
Glenn Russell Dubin’s Highbridge Capital Management is the largest shareholding institution (amongst those we track) at Theravance Inc (NASDAQ:THRX) with 37.9 million shares, valued at an estimate $54.5 million, after reporting a 76% holding increment at the end of the second filling period of 2014.
Theravance Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Disclosure: The author, Jodor Jalit, holds no position in any stocks or funds mentioned.